Event Description

According to the MBGH’s 2024/25 member survey, 98% of employers indicate drug prices are a significant threat to the affordability of health care. While 67% of employers are currently promoting and including biosimilars on their formulary, another 23% are considering it. This is good news, and especially relevant since employers, as a fiduciary, must make prudent decisions and act in the best interests of beneficiaries and the plan. Yet there are still challenges that must be addressed – for example, is formulary access to biosimilars enough? Biosimilars hold the promise of making life-saving medications more affordable while treating chronic diseases. They generate cost savings by increasing competition and lowering prices. However, reference products (brand names) still retain most of the market, even when biosimilars are placed on formulary. Why? Because employers receive significant rebates from PBMs for the reference products. This webinar offers valuable insights and serves as a call to action to safeguard the sustainability of the biosimilars market, while ensuring an employer’s fiduciary responsibility.

This program is only available virtually.